LEIDEN, THE NETHERLANDS — Dairy protein manufacturer Vivici raised $33.7 million (€32.5 million) in Series A funding led by APG on behalf of ABP, a pension fund, and Invest-NL.

The company said funding will expand the ingredient startup into new international markets, launch its second dairy protein ingredient and establish its manufacturing capabilities.

“With this investment, we will continue on our path to turning the promise of precision fermentation into a commercial reality,” said Stephan van Sint Fiet, chief executive officer of Vivici. “This fundraise demonstrates the confidence investors have in both our mission and our capabilities. With our Vivitein protein platform, we’re bringing a new standard of protein to the market — one that will become a mainstay of consumer protein products.”

With the recent funding, Vivici is now offering its Vivitein BLG ingredient in the US market.

Vivitein BLG is the company’s flagship ingredient under its Vivitein protein platform. Vivitein BLG is an isolated whey protein that is produced using precision fermentation. It may be used in such applications as clear water-based protein beverages, clean protein powders for muscle-building and rapid absorption and vegan protein bars.

Vivici said it is planning to launch a portfolio of ingredient products that will include a lactoferrin ingredient, specifically Vivitein LF, later this year.